Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
- 31 July 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 16-23
- https://doi.org/10.1016/s0037-1963(01)90126-x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Blood, 2000
- Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospectsCurrent Opinion in Cell Biology, 2000
- Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced CancerJournal of Clinical Oncology, 2000
- The Hallmarks of CancerCell, 2000
- Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic DevelopmentJournal of Clinical Oncology, 1999
- RASand Leukemia: From Basic Mechanisms to Gene-Directed TherapyJournal of Clinical Oncology, 1999
- Multiple Myeloma: Increasing Evidence for a Multistep Transformation ProcessBlood, 1998
- Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoBJournal of Biological Chemistry, 1997
- Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeuticCell, 1994